|
1
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistic, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eschwège P, Dumas F, Blanchet P, Le Maire
V, Benoit G, Jardin A, Lacour B and Loric S: Haematogenous
dissemination of prostatic epithelial cells during radical
prostatectomy. Lancet. 346:1528–1530. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Holmgren L, O'Reilly MS and Folkman J:
Dormancy of micrometastases: Balanced proliferation and apoptosis
in the presence of angiogenesis suppression. Nat Med. 1:149–153.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shapiro J, Jersky J, Katzav S, Feldman M
and Segal S: Anesthetic drugs accelerate the progression of
postoperative metastases of mouse tumors. J Clin Invest.
68:678–685. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Page GG, Blakely WP and Ben-Eliyahu S:
Evidence that post-operative pain is a mediator of the
tumor-promoting effects of surgery in rats. Pain. 90:191–199. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ben-Eliyahu S: The price of anticancer
intervention. Does surgery promote metastasis? Lancet Oncol.
3:578–579. 2002.PubMed/NCBI
|
|
7
|
Biki B, Mascha E, Moriarty DC, Fitzpatrick
JM, Sessler DI and Buggy DJ: Anesthetic technique for radical
prostatectomy surgery affects cancer recurrence: A retrospective
analysis. Anesthesiology. 109:180–187. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tsui BC, Rashiq S, Schopflocher D, Murtha
A, Broemling S, Pillay J and Finucane BT: Epidural anesthesia and
cancer recurrence rates after radical prostatectomy. Can J Anaesth.
57:107–112. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Forget P, Vandenhende J, Berliere M,
Machiels JP, Nussbaum B, Legrand C and De Kock M: Do intraoperative
analgesics influence breast cancer recurrence after mastectomy? A
retrospective analysis. Anesth Analg. 110:1163–1635. 2010.
View Article : Google Scholar
|
|
10
|
Chen X, Lu P, Chen L, Yang SJ, Shen HY, Yu
DD, Zhang XH, Zhong SL, Zhao JH and Tang JH: Perioperative
propofol-paravertebral anesthesia decreases the metastasis and
progression of breast cancer. Tumour Biol. 36:8259–8266. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Melamed R, Bar-Yosef S, Shakhar G, Shakhar
K and Ben-Eliyahu S: Suppression of natural killer cell activity
and promotion of tumor metastasis by ketamine, thiopental, and
halothane, but not by propofol: Mediating mechanisms and
prophylactic measures. Anesth Analg. 97:1331–1339. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kirkpatrick K, Ogunkolade W, Elkak A,
Bustin S, Jenkins P, Ghilchik M and Mokbel K: The mRNA expression
of cyclo-oxygenase-2 (COX-2) and vascular endothelia growth factor
(VEGF) in human breast cancer. Curr Med Res Opin. 18:237–241. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chang SH, Liu CH, Conway R, Han DK,
Nithipatikom K, Trifan OC, Lane TF and Hla T: Role of prostaglandin
E2-dependent angiogenic switch in cyclooxygenase 2-induced breast
cancer progression. Proc Natl Acad Sci USA. 101:591–596. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Simeone AM, Li YJ, Broemeling LD, Johnson
MM, Tuna M and Tari AM: Cyclooxygenase-2 is essential for HER-2/neu
to suppress N-(4-hydroxyphenyl)retinamide apoptotic effects in
breast cancer cells. Cancer Res. 64:1224–1228. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Barnes N, Haywood P, Flint P, Knox WF and
Bundred NJ: Survivin expression in in situ and invasive breast
cancer relates to COX-2 expression and DCIS recurrence. Br J
Cancer. 94:253–258. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Harris RE: Cyclooxygenase-2 (cox-2)
blockade in the chemoprevention of cancers of the colon, breast,
prostate, and lung. Inflammopharmacology. 17:55–67. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Qin G, Xu F, Qin T, Zheng Q, Shi D, Xia W,
Tian Y, Tang Y, Wang J, Xiao X, et al: Palbociclib inhibits
epithelial-mesenchymal transition and metastasis in breast cancer
via c-Jun/COX-2 signaling pathway. Oncotarget. 6:41794–41808. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hugo HJ, Saunders C, Ramsay RG and
Thompson EW: New insights on COX-2 in chronic inflammation driving
breast cancer growth and metastasis. J Mammary Gland Biol
Neoplasia. 20:109–119. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu CH, Chang SH, Narko K, Trifan OC, Wu
MT, Smith E, Haudenschild C, Lane TF and Hla T: Overexpression of
cyclooxygenase-2 is sufficient to induce tumorigenesis in
transgenic mice. J Biol Chem. 267:18563–18569. 2001. View Article : Google Scholar
|
|
20
|
Harris RE, Kasbari S and Farrar WB:
Prospective study of nonsteroidal anti-inflammatory drugs and
breast cancer. Oncol Rep. 6:71–73. 1999.PubMed/NCBI
|
|
21
|
Joo YE, Rew JS, Seo YH, Choi SK, Kim YJ,
Park CS and Kim SJ: Cyclooxygenase-2 overexpression correlates with
vascular endothelial growth factor expression and tumor
angiogenesis in gastric cancer. J Clin Gastroenterol. 37:28–33.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wise H: Lack of interaction between
prostaglandin E2 receptor subtypes in regulating adenylyl cyclase
activity in cultured rat dorsal root ganglion cells. Eur J
Pharmacol. 535:69–77. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Komuro M, Kamiyama M, Furuya Y, Takihana
Y, Araki I and Takeda M: Gene and protein expression profiles of
prostaglandin E2 receptor subtypes in the human corpus cavernosum.
Int J Impot Res. 18:275–281. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Deasy BM, O'Sullivan-Coyne G, O'Donovan
TR, McKenna SL and O'Sullivan GC: Cyclooxygenase-2 inhibitors
demonstrate anti-proliferative effects in oesophageal cancer cells
by prostaglandin E(2)-independent mechanisms. Cancer Lett.
256:246–258. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kellesarian SV, Al-Kheraif AA, Vohra F,
Ghanem A, Malmstrom H, Romanos GE and Javed F: Cytokine profile in
the synovial fluid of patients with temporomandibular joint
disorders: A systematic review. Cytokine. 77:98–106. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ren XF, Li WZ, Meng FY and Lin CF:
Differential effects of propofol and isoflurane on the activation
of T-helper cells in lung cancer patients. Anaesthesia. 65:478–482.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Miyata T, Kodama T, Honma R, Nezu Y,
Harada Y, Yogo T, Hara Y and Tagawa M: Influence of general
anesthesia with isoflurane following propofol-induction on natural
killer cell cytotoxic activities of peripheral blood lymphocytes in
dogs. J Vet Med Sci. 75:917–921. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mammoto T, Mukai M, Mammoto A, Yamanaka Y,
Hayashi Y, Mashimo T, Kishi Y and Nakamura H: Intravenous
anesthetic, propofol inhibits invasion of cancer cells. Cancer
Lett. 184:165–170. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tsuchiya M, Asada A, Arita K, Utsumi T,
Yoshida T, Sato EF, Utsumi K and Inoue M: Induction and mechanism
of apoptotic cell death by propofol in HL-60 cells. Acta
Anaesthesiol Scand. 46:1068–1074. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Miao Y, Zhang Y, Wan H, Chen L and Wang F:
GABA-receptor agonist, propofol inhibits invasion of colon
carcinoma cells. Biomed Pharmacother. 64:583–588. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kushida A, Inada T and Shingu K:
Enhancement of antitumor immunity after propofol treatment in mice.
Immunopharmacol Immunotoxicol. 29:477–486. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Inada T, Kubo K and Shingu K: Possible
link between cyclooxygenase-inhibiting and antitumor properties of
propofol. J Anesth. 25:569–575. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tchirkov A, Khalil T, Chautard E, Mokhtari
K, Véronèse L, Irthum B, Vago P, Kémény JL and Verrelle P:
Interleukin-6 gene amplification and shortened survival in
glioblastoma patients. Br J Cancer. 96:474–476. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Singh B, Berry JA, Vincent LE and Lucci A:
Involvement of IL-8 in COX-2-mediated bone metastases from breast
cancer. J Surg Res. 134:44–51. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chou WY, Chuang KH, Sun D, Lee YH, Kao PH,
Lin YY, Wang HW and Wu YL: Inhibition of PKC-Induced COX-2 and IL-8
expression in human breast cancer cells by glucosamine. J Cell
Physiol. 230:2240–2251. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Simeone AM, Nieves-Alicea R, McMurtry VC,
Colella S, Krahe R and Tari AM: Cyclooxygenase-2 uses the protein
kinase C/interleukin-8/urokinase-type plasminogen activator pathway
to increase the invasiveness of breast cancer cells. Int J Oncol.
30:785–792. 2007.PubMed/NCBI
|
